MARAGANORE JOHN 4

What Happened
John Maraganore, a director of Kymera Therapeutics (KYMR), received a grant of stock options covering 6,068 underlying shares on 2026-06-24. The reported acquisition price is $0.00 (no cash exchanged at grant); this is a derivative award (stock option), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-24; filing date: 2026-06-25 (appears timely).
• Award: 6,068 underlying shares; reported price/value at grant: $0.00.
• Shares owned after transaction: Not specified in this Form 4 filing.
• Footnote: The underlying shares vest in full upon the earlier of (i) June 24, 2027 or (ii) the date of the next annual meeting of stockholders.
• Transaction type: Derivative grant/award (stock option); no exercise or sale reported.

Context
This was a director compensation award (stock option grant) rather than a purchase or sale. The option will vest per the footnote schedule and would require exercise (and typically payment of an exercise price) before Maraganore could convert it into common shares. Director grants are common as part of board compensation and do not by themselves indicate insider buying or selling sentiment.